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Summary
Background Cerebral cavernous malformations (CCMs) can cause symptomatic intracranial haemorrhage (ICH), but 
the estimated risks are imprecise and predictors remain uncertain. We aimed to obtain precise estimates and 
predictors of the risk of ICH during untreated follow-up in an individual patient data meta-analysis.
Methods We invited investigators of published cohorts of people aged at least 16 years, identiﬁ ed by a systematic 
review of Ovid MEDLINE and Embase from inception to April 30, 2015, to provide individual patient data on clinical 
course from CCM diagnosis until ﬁ rst CCM treatment or last available follow-up. We used survival analysis to 
estimate the 5-year risk of symptomatic ICH due to CCMs (primary outcome), multivariable Cox regression to identify 
baseline predictors of outcome, and random-eﬀ ects models to pool estimates in a meta-analysis.
Findings Among 1620 people in seven cohorts from six studies, 204 experienced ICH during 5197 person-years of 
follow-up (Kaplan-Meier estimated 5-year risk 15·8%, 95% CI 13·7–17·9). The primary outcome of ICH within 
5 years of CCM diagnosis was associated with clinical presentation with ICH or new focal neurological deﬁ cit (FND) 
without brain imaging evidence of recent haemorrhage versus other modes of presentation (hazard ratio 5·6, 95% CI 
3·2–9·7) and with brainstem CCM location versus other locations (4·4, 2·3–8·6), but age, sex, and CCM multiplicity 
did not add independent prognostic information. The 5-year estimated risk of ICH during untreated follow-up was 
3·8% (95% CI 2·1–5·5) for 718 people with non-brainstem CCM presenting without ICH or FND, 8·0% (0·1–15·9) 
for 80 people with brainstem CCM presenting without ICH or FND, 18·4% (13·3–23·5) for 327 people with non-
brainstem CCM presenting with ICH or FND, and 30·8% (26·3–35·2) for 495 people with brainstem CCM presenting 
with ICH or FND.
Interpretation Mode of clinical presentation and CCM location are independently associated with ICH within 5 years 
of CCM diagnosis. These ﬁ ndings can inform decisions about CCM treatment.
Funding UK Medical Research Council, Chief Scientist Oﬃ  ce of the Scottish Government, and UK Stroke Association.
Copyright © Horne et al. Open Access article distributed under the terms of CC BY
Introduction
Cerebral cavernous malformations (CCMs) are the 
second commonest incidental vascular ﬁ nding—after 
aneurysms1—on brain MRI, with a prevalence of one in 
625 neurologically asymptomatic people.2,3 Because brain 
MRI is needed for diagnosis of CCMs without pathological 
examination,4 the number of people in whom CCM has 
been detected has risen since the advent of MRI.5,6
CCMs can be asymptomatic or can cause epileptic 
seizures,7 stroke due to symptomatic intracranial 
haemorrhage (ICH),8 or new focal neurological deﬁ cit 
(FND) without evidence on brain imaging of recent 
haemorrhage.8 As MRI use increases over time,9 so too 
does the need for information about the magnitude and 
predictors of the risk of ICH or FND from CCMs. These 
risks can inform decisions about whether to treat CCMs 
with neurosurgical excision or stereotactic radiosurgery, 
although the use of the latter remains controversial and 
neither treatment has been assessed in a randomised 
trial.10
Some cohort studies have estimated the risk of ICH 
from untreated CCMs. However, ﬁ ndings from a recent 
systematic review11 showed that these studies were mostly 
retrospective hospital-based series, with sample sizes not 
exceeding 139 people and short durations of follow-up, 
without clearly deﬁ ned diagnostic criteria or outcome 
events,8 and in which several diﬀ erent statistical methods 
were used to calculate the risk and predictors of ICH. 
Findings from these studies have left uncertainty about 
the magnitude of the risk of ICH and its predictors. 
Additionally, there remains an absence of prediction 
models.
Therefore, we sought to address these uncertainties by 
undertaking a systematic review and meta-analysis of 
individual patient data from cohort studies of people 
with CCMs with similar designs and outcome 
deﬁ nitions.12,13 By using consistent methods of analysis, 
we aimed to estimate the risks of ﬁ rst ICH or FND 
during follow-up and to identify predictors of these 
outcomes.
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Methods
Study design
We undertook this study according to a protocol 
ﬁ nalised on May 9, 2012, which was approved by the 
Cerebral Cavernous Malformations Individual Patient 
Data Meta-analysis Collaborators. Two authors with 
training in undertaking systematic reviews (MAH and 
RA-SS) used electronic search strategies (appendix 
p 2)11 to search Ovid MEDLINE and Embase from 
inception until April 30, 2015, for published cohort 
studies; they screened the biblio graphies of studies for 
other potentially eligible cohorts, established their 
eligibility, and resolved any disagreements by 
discussion. Cohorts were eligible for inclusion 
regardless of language of publication if they included 
people aged 16 years or older—a common age cutoﬀ  for 
transition to adult services14—at the time of a deﬁ nite 
diagnosis of CCM conﬁ rmed by brain MRI, and if they 
included at least symptomatic ICH due to CCM and 
death as outcomes after an inception point of ﬁ rst 
diagnosis of CCM but before ﬁ rst CCM treatment with 
neurosurgical excision or stereotactic radiosurgery. 
After sending a copy of the protocol and invitation to 
collaborate to the corresponding authors of the reports 
that described cohorts that were eligible for inclusion, 
followed by one reminder, we included cohorts from 
studies for which the study investigators conﬁ rmed 
their eligibility and provided patient-level data on 
baseline covariates, outcomes, and CCM treatment. We 
were unable to use aggregate data from cohorts for 
which individual patient data were unavailable because 
time-to-event analyses require patient-level data. 
Research ethics committees or other entities overseeing 
the use of patients’ data approved the collaborating 
cohorts. Cohorts shared only anonymised data, so neither 
individual consent nor speciﬁ c approval for this 
individual patient data meta-analysis were required.15
Data collection
Collaborating cohorts provided patient-level data at 
baseline (sex, mode of symptomatic presentation leading 
to diagnosis of CCMs, age at CCM diagnosis, date of 
CCM diagnosis, CCM multiplicity, and primary CCM 
location) and during follow-up (all outcome types and 
dates, all treatment types and dates, and date of last 
follow-up) for time-to-event analyses. We excluded people 
who had been ﬁ rst diagnosed when younger than 
16 years or who had already received treatment for CCMs. 
Investigators in each cohort distinguished two clinical 
events attributable to CCMs, at presentation and during 
follow-up, where possible, according to the Angioma 
Alliance deﬁ nitions.8 ICH was deﬁ ned as acute or 
subacute onset of symptoms of haemorrhage with recent 
extralesional or intralesional haemorrhage conﬁ rmed by 
investigations (CT or MRI, or pathological examination 
at autopsy). FND was deﬁ ned as new or worsened 
neurological deﬁ cit referable to the CCM anatomical 
location with or without timely investigation to rule out 
evidence of recent haemorrhage.8 We checked data from 
each cohort for internal consistency against published 
reports of the cohort and resolved any queries with the 
relevant collaborators. For missing data, we contacted 
collaborators to request the missing values. We assessed 
the risk of bias of each cohort according to an eight-item 
instrument published by the Cochrane Methods Bias 
group.16
Outcomes
The primary outcome was ﬁ rst symptomatic ICH due to 
CCM. The secondary outcome was a composite of ﬁ rst 
symptomatic ICH or FND due to CCM. Time-to-event 
analyses started at diagnosis of CCM and terminated at 
For the study protocol see 
http://www.saivms.scot.nhs.uk/
resPaper.asp
See Online for appendix
1904 studies identified from electronic database 
 searches 
1725 titles and abstracts screened  
39 full text articles assessed for eligibility  
22 studies eligible for inclusion and study 
 investigators invited to share individual 
 patient data  
179 duplicates removed   
1686 studies excluded   
17 full text articles excluded* 
 4 already included in a separate 
  publication of an eligible cohort 
 2 diagnosis not certain 
 5 risk calculated retrospectively, assuming
  CCM present from birth 
 3 outcome events were not objective 
  and symptomatic 
 3 duration of follow-up was not 
  adequately quantified
6 studies of 7 cohorts‡ included for which 
 individual patient data were provided 
 (1620 patients)§  
16 studies excluded because 
 investigators did not provide 
 individual patient data (1337 patients)† 
  3 agreed initially, but no response 
   subsequently 
  2 data no longer available 
  1 clinical data not available
  10 no response to invitation 
 
Figure 1: Study ﬂ owchart
CCM=cerebral cavernous malformation. *See appendix pp 18–19. †See appendix 
pp 19–20 for references. ‡One eligible study provided data from two time 
periods, which are included as two separate cohorts. §See appendix p 20.
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the earliest occurrence of ICH only for the analysis of the 
primary outcome. For the secondary outcome, these 
analyses were terminated at the earliest occurrence of 
ICH or FND. If an outcome did not occur, we censored 
analyses at the earliest occurrence of CCM treatment, 
death unrelated to CCM, last available follow-up, or 
5 years after CCM diagnosis.
Statistical analysis
We agreed a detailed statistical analysis plan with 
collaborators in Oct 25, 2013, before data analysis began. 
We categorised mode of presentation as one of four 
mutually exclusive categories: ICH, FND, epileptic 
seizure if the seizure was neither symptomatic of a 
concomitant ICH nor more likely to be due to another 
cause, or incidental if a person was asymptomatic or if 
their symptoms (eg, headache) could not be ascribed to 
the underlying CCM. We attributed one CCM location to 
people harbouring more than one CCM by using the 
location of the symptomatic CCM; when a person 
presented asymptomatically with more than one CCM, 
brainstem CCM location took precedence since this 
location seemed to be a predictor of ICH from a systematic 
review of aggregate data from existing studies.11 We 
calculated the relative risk of having a CCM located in the 
brainstem for ICH or FND versus other presentations.
We used survival analysis to estimate the 5-year risk of 
symptomatic ICH attributable to CCMs. The inception 
point was the earliest date of deﬁ nite diagnosis of CCMs 
by radiographic or pathological investigation.
We prespeciﬁ ed ﬁ ve potential predictors for 
investigation of their association with outcome on the 
basis of their clinical relevance, likelihood of being 
associated with outcome,11,17–20 reliability, accuracy of 
measurement, completeness, and availability at the time 
of diagnosis.21 Core predictors were mode of presentation 
(ICH or FND vs other) and CCM location (brainstem vs 
other). We dichotomised mode of clinical presentation 
because previous ICH seemed to be a predictor from a 
systematic review of aggregate data from existing studies, 
and included FND because in certain circumstances 
FND can suggest undetected ICH.8 Putative predictors 
were sex (female vs male), CCM multiplicity (more than 
one vs one), and increasing age at diagnosis (which we 
treated as a continuous variable in association analyses).22 
We did separate univariable analyses of each cohort and 
the pooled data. We used Cox regression to calculate the 
unadjusted hazard ratios (HRs) for each predictor. We 
used log-minus-log plots to check that the proportional-
hazards assumption was met before undertaking Cox 
proportional-hazards multivariable regression. In the 
statistical analysis plan, we speciﬁ ed that in multivariable 
adjusted analyses, we would enter the core predictors 
into the model ﬁ rst; then, to ascertain whether any of the 
remaining three putative predictors added signiﬁ cant 
information over and above the core predictors, we 
entered each putative predictor into the model, provided 
the conventional rule that there should be at least ten 
outcome events per predictor was fulﬁ lled.21,23 We 
followed this clinically driven approach because we were 
Mode of presentation leading to CCM diagnosis
Incidental (n=461) Seizure (n=337) ICH (n=576) FND (n=246) Total (n=1620)
Age at diagnosis (years) 51 (37–62) 42 (30–57) 41 (32–51) 47 (36–60) 45 (33–58)
Sex
Female 259 (56%) 160 (47%) 310 (54%) 138 (56%) 867 (54%)
Male 202 (44%) 177 (53%) 266 (46%) 108 (44%) 753 (46%)
More than one CCM 77 (17%) 70 (21%) 90 (16%) 45 (18%) 282 (17%)
Primary CCM location
Lobar 300 (65%) 289 (86%) 154 (27%) 69 (28%) 812 (50%)
Deep 46 (10%) 18 (5%) 41 (7%) 24 (10%) 129 (8%)
Cerebellum 50 (11%) 15 (4%) 22 (4%) 17 (7%) 104 (6%)
Brainstem 65 (14%) 15 (4%) 359 (62%) 136 (55%) 575 (35%)
CCM management
Surgery or stereotactic radiosurgery 28 (6%) 77 (23%) 172 (30%) 35 (14%) 312 (19%)
Conservative management 433 (94%) 260 (77%) 404 (70%) 211 (86%) 1308 (81%)
First outcome event during untreated follow-up*
ICH 12 (3%) 12 (4%) 151 (26%) 29 (12%) 204 (13%)
FND 10 (2%) 3 (1%) 18 (3%) 24 (10%) 55 (3%)
None 439 (95%) 322 (96%) 407 (71%) 193 (78%) 1361 (84%)
Censored follow-up (years) 3·9 (2·0–5·0) 3·6 (1·5–5·0) 3·0 (1·1–5·0) 4·2 (2·1–5·0) 3·5 (1·6–5·0)
Data are median (IQR) or number (%). Some percentages do not add up to 100 because of rounding. CCM=cerebral cavernous malformation. FND=non-haemorrhagic focal 
neurological deﬁ cit. ICH=intracranial haemorrhage. *1620 people contributed data on the occurrence of ICH outcomes. 640 people contributed data on the occurrence of the 
composite outcome of ICH or FND. 
Table 1: Baseline and follow-up characteristics 
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undertaking a two-stage individual patient data meta-
analysis and we were aware that the number of events 
during follow-up in each individual cohort would be 
insuﬃ  cient to permit a full data-driven selection of 
variables to be included in the model.
We did two-stage meta-analyses of the univariable 
associations of each of the ﬁ ve predictors with outcome, 
in which we derived study-speciﬁ c unadjusted HRs and 
combined them using a random-eﬀ ects model to 
generate a weighted unadjusted pooled HR.24,25 We did 
meta-analyses for each of the three putative predictors, 
both unadjusted and adjusted for the core predictors. We 
assessed heterogeneity between studies using the 
I² index of inconsistency, which measures the proportion 
of total variation in study estimates that is due to 
heterogeneity.26,27
We planned to build prognostic models of the estimated 
5-year risk of ICH after diagnosis on the basis of the 
ﬁ ndings of the multivariable analyses and meta-
analyses.23,28,29 Because we had ﬁ ve potential predictors 
and outcome events tend to be infrequent, we used the 
entire dataset to develop our models, rather than split it 
into a derivation and a test set. For internal validation, we 
used bootstrapping to derive 95% CIs for the multivariable 
Cox regression analyses, by creating 10 000 random 
samples of the same size as the study cohort using 
sampling with replacement. We used Kaplan-Meier plots 
to assess the separation achieved by prognostic models, 
and life tables to estimate annual hazard rates of 
experiencing an ICH within 5 years of diagnosis of 
CCMs.
We did descriptive and survival analyses using IBM 
SPSS Statistics 19 and 21, and used Stata IC12 for the 
individual patient data meta-analysis.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, writing 
of the report, or in the decision to submit for publication. 
All authors had full access to all the data in the study, but 
only MAH and GDM analysed the data; the corresponding 
author had ﬁ nal responsibility for the decision to submit 
for publication. 
Results
From 22 publications of potentially eligible cohorts that 
included 2957 people (ﬁ gure 1; appendix p 3), six research 
groups provided published data on seven cohorts 
involving 1620 people for inclusion in this meta-analysis 
(appendix p 4).11,17–20,30 For missing data, in every instance 
the investigators of the original study were able to check 
their database and provide the missing values for all 
covariates. Of the 16 research groups who did not join the 
collaboration, whose studies involved 1337 people (45% of 
the published data), three groups agreed to collaborate 
but did not share data, two groups no longer had access 
to their data, one group did not have clinical data 
Figure 2: Forest plots of associations between mode of presentation and cerebral cavernous malformation 
location with primary and secondary outcomes
Plots show cohort-level and pooled estimates of associations between ICH or FND at presentation (A and C) or 
brainstem CCM location (B and D) and outcome during 5 years of follow-up. The area of each shaded box is 
proportional to the weight of the cohort it represents. CCM=cerebral cavernous malformation. FND=focal 
neurological deﬁ cit. HR=hazard ratio. ICH=intracranial haemorrhage.
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available, and ten groups did not respond to our 
invitations (ﬁ gure 1; appendix pp 19–20).
Five cohorts were from tertiary referral centres (Toronto 
Western Hospital, ON, Canada, 1987–2007, n=345; Mayo 
Clinic, Rochester, MN, USA, 1984–98, n=267; Hôpital 
Lariboisière, Paris, France, 1994–2011, n=81; Seoul 
National University Hospital, Seoul, South Korea, 
1998–2010, n=326; and Beijing Tiantan Hospital, Beijing, 
China, 1985–2012, n=306) and one was from the Scottish 
population (1999–2003, n=135). Data from a seventh 
cohort (Scottish population, 2006–10, n=160) and 63% 
(217 of 345 adults) of the Toronto cohort were previously 
unpublished. The Beijing cohort was restricted to adults 
with a brainstem CCM. Follow-up was prospective in the 
population-based cohorts11 and one of the hospital-based 
cohorts,20 both retrospective and prospective in another 
hospital-based cohort,17 and retrospective in the 
remainder (appendix p 3).18,19,30 We did not identify 
problems (eg, incompatibility with diﬀ erent study 
inception points or diﬀ erences in CCM, ICH, or FND 
deﬁ nitions) when we checked the individual patient data. 
We used the date of symptom onset leading to diagnosis 
of CCM or the date of ﬁ rst medical assessment for 
27 people without a date of diagnosis of CCMs in 
one cohort.17 All seven cohorts recorded FND as a mode 
of clinical presentation, but four cohorts did not record 
FND during follow-up.18–20,30 Risk of bias in the seven 
cohorts was low (appendix p 5).
The median age at diagnosis was 45 years (range 
16–91), 867 (54%) of people were women, 822 (51%) 
presented with ICH or FND, 282 (17%) had multiple 
CCMs, and 575 (35%) had CCMs located in the brainstem 
(table 1). People who had presented with ICH or FND 
were more likely to have a brainstem CCM than people 
who presented with a seizure or incidentally (prevalence 
ratio 6·0, 95% CI 4·8–7·5). The primary outcome event 
was recorded in all seven cohorts; follow-up ended at the 
occurrence of the ﬁ rst ICH outcome event (n=204) or 
censoring (owing to CCM treatment [n=193], death 
unrelated to ICH or FND [n=46], end of follow-up before 
5 years [n=596], or end of follow-up at 5 years [n=581]). 
Total follow-up was 5197 person-years (median 3·5 years 
per person, IQR 1·6–5·0, 70% completeness31 of all 
potential follow-up). Only the Scottish and Toronto 
cohorts recorded both ICH and FND during follow-up 
(in 640 [40%] of 1620 included people), and so we 
restricted analysis of the secondary composite outcome 
event of ICH or FND to these cohorts.
204 of 1620 people experienced ICH within 5 years of 
diagnosis of CCMs (Kaplan-Meier estimated 5-year risk 
15·8%, 95% CI 13·7–17·9), four of which were fatal 
(1-month case fatality rate after ICH due to CCM; 2·0% 
[95% CI 0·1–3·9]). The estimated risk of ﬁ rst ICH 
within 5 years of diagnosis of CCM in the pooled dataset 
was higher for people presenting with ICH or FND 
versus other modes of presentation (26·4% [95% CI 
23·1–29·7] vs 4·3% [2·5–6·1]; pooled unadjusted HR 5·6 
[95% CI 3·2–9·7]) and for people with a primary CCM 
location in the brainstem versus another location (27·7% 
[95% CI 23·6–31·8] vs 8·2% [6·2–10·2]; pooled 
unadjusted HR 4·4, [95% CI 2·3–8·6]); these ﬁ ndings 
were similar in individual cohorts (ﬁ gure 2; appendix 
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Figure 3: Kaplan-Meier plots of progression to intracranial haemorrhage or to intracranial haemorrhage or 
focal neurological deﬁ cit
Plots show the proportion of people progressing to ICH (A) or ICH or FND (B) during follow-up, stratiﬁ ed by ICH or 
FND presentation from brainstem CCMs, ICH or FND presentation from non-brainstem CCMs, other presentation 
from brainstem CCMs, and other presentation from non-brainstem CCMs. CCM=cerebral cavernous malformation. 
FND=focal neurological deﬁ cit. HR=hazard ratio. ICH=intracranial haemorrhage. 
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pp 6–7). We found no evidence—even after multivariable 
adjustment for the two core predictors—that age, sex, or 
CCM multiplicity aﬀ ected the risk of ICH, and these 
ﬁ ndings were generally consistent between cohorts 
(appendix pp 8–10).
We found no evidence of publication bias in a funnel 
plot of the HR for the primary outcome by mode of 
presentation (appendix p 11). We assessed risk of 
publication bias by inspecting a funnel plot of the HR 
against the standard error of log (HR). As a sensitivity 
analysis, we repeated the meta-analyses of the ﬁ ve 
cohorts with proportionally fewer outcome events. 
Although the Chinese cohort, which consisted entirely of 
adults with brainstem CCMs, contributed 44% of ICHs 
during follow-up (90 of 204), a sensitivity analysis 
excluding the Chinese and South Korean cohorts—both 
of which contained proportionally more people with ICH 
during follow-up than the other ﬁ ve cohorts (South Korea 
52 of 204)—produced similar results (data not shown).
The ﬁ ndings of the univariable and multivariable 
survival analyses led us to create two prognostic models, 
using the two core predictors—mode of clinical 
presentation and CCM location—in multivariable Cox 
regression analyses. By dichotomising each of these 
predictors, we identiﬁ ed four prognostic subgroups with 
signiﬁ cant diﬀ erences in their risks of outcomes 
according to stratiﬁ ed Kaplan-Meier plots (ﬁ gure 3; log-
rank p<0·0001 for both proportion progressing to ICH 
and proportion progressing to ICH or FND) or according 
to Cox regression of 5-year event rates and HRs (table 2), 
after checking proportional hazards assumptions were 
met (appendix p 12). People with CCMs outside the 
brainstem who had not presented with ICH or FND were 
in the majority and had the lowest risk, whereas people 
with brainstem CCMs presenting with ICH or FND were 
the highest-risk group (ﬁ gure 3; table 2; appendix p 13).
Estimates of the annual risk of ICH during each year of 
follow-up decreased from 6·2% (95% CI 4·9–7·4) in the 
ﬁ rst year of follow-up to 2·0% (0·9–3·0) in the ﬁ fth year 
overall (p<0·0001; appendix p 14). This reduction was 
evident only in people presenting with ICH or FND 
(appendix p 15).
In the subgroup of 640 people with data recorded for 
the composite secondary outcome of ICH or FND, 
36 people had an ICH and 52 had an FND during follow-
up. In this subgroup, the magnitude, direction, and 
consistency of associations of the core and putative 
predictors with the secondary outcome were similar to 
the primary analysis (table 2; ﬁ gure 2; appendix pp 8–10 
and 16–17), but the event rate was higher (17·0%, 95% CI 
13·6–20·3). 
Discussion
To the best of our knowledge, this is the largest analysis 
of the clinical course of untreated CCMs so far, in which 
we found that brainstem CCM location and CCM 
presentation with ICH or FND were independently 
associated with the occurrence of ICH after diagnosis of 
CCMs, whereas age, sex, and CCM multiplicity did not 
contribute any additional prognostic information. The 
risk of ICH during 5 years of follow-up diﬀ ered 
signiﬁ cantly according to the possession of either, or 
both, of these risk factors; annual ICH incidence 
decreased over time in people initially presenting with 
ICH or FND.
This study has the following strengths. The sample size 
of the pooled cohort was large and contained unpublished 
data in addition to data from people who were already 
described in published studies. There was 100% 
completeness for data on baseline covariates (appendix 
p 4). We ensured that outcome event deﬁ nitions and 
statistical methods of survival analysis were consistent 
across the collaborating cohorts. The duration and 
completeness of follow-up enabled us to construct 5-year 
survival curves with more precise estimations of 
associations and event incidences than previously 
possible. The risk of bias in the participating cohorts was 
low, and the ﬁ ndings were consistent in retrospective 
hospital-based cohorts and prospective population-based 
cohorts (ﬁ gure 2). These strengths in design are 
reinforced by robustness of the results when compared 
with ﬁ ndings from individual cohorts for which event 
rates of variable magnitude were estimated and for which 
ﬁ ndings of associations between outcome and our core 
and putative predictors have been inconsistent.11
This study has some limitations. Not all of the eligible 
published cohorts had retained data to share in this 
Number of 
people (%)
Number of 
outcome 
events during 
5-year 
follow-up
Hazard ratio 
(95% CI)*
Estimated 5-year 
risk (95% CI)
Primary outcome: ICH (n=1620)
ICH or FND presentation, brainstem 
CCM location
495 (31%) 135 10·2 (5·0–23·9) 30·8% (26·3–35·2)
ICH or FND presentation, other CCM 
location
327 (20%) 45 5·6 (3·7–9·4) 18·4% (13·3–23·5)
Other presentation, brainstem CCM 
location
80 (5%) 4 1·8 (1·3–2·6) 8·0% (0·1–15·9)
Other presentation, other CCM 
location
718 (44%) 20 Reference 3·8% (2·1–5·5)
Secondary outcome: ICH or FND (n=640)
ICH or FND presentation, brainstem 
CCM location
113 (18%) 48 16·3 (5·8–53·7) 50·7% (40·1–61·4)
ICH or FND presentation, other CCM 
location
141 (22%) 24 5·1 (2·9–10·0) 22·4% (14·2–30·6)
Other presentation, brainstem CCM 
location
31 (5%) 5 3·2 (2·0–5·4) 22·9% (3·7–42·2)
Other presentation, other CCM 
location
355 (55%) 11 Reference 3·7% (1·5–5·9)
CCM=cerebral cavernous malformation. FND=non-haemorrhagic focal neurological deﬁ cit. ICH=intracranial 
haemorrhage. *Bootstrapped 95% CIs: 10 000 samples with replacement.
Table 2: Hazard ratios and estimated 5-year risks of outcome events for core predictors in prognostic 
models
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collaborative analysis. Outcome data were available on 
both ICH and FND for only 40% of the included people, 
but these data were suﬃ  cient to quantify event rates with 
reasonable precision and show associations between 
predictors and outcomes that were consistent with the 
primary analysis. Our statistical analysis assumed that 
censoring was non-informative, but even if informative 
censoring did occur (ie, because of treatment of CCMs 
that were in the brainstem or that presented with ICH or 
FND),32 it happened infrequently. We set a lower limit of 
16 years for age at diagnosis, to focus this study on 
patients who were referred to neurologists and 
neurosurgeons who care for adults (ie, age at least 
16 years), resulting in the exclusion of data on 46 (3%) of 
the 1666 people available in the collaborating cohorts; 
however, the proportion of events in people aged 
16–18 years was comparable with the rest of the cohort 
(data not shown).
The main implication of our ﬁ ndings for clinical 
practice is that people with CCMs can be stratiﬁ ed into 
four groups to predict the 5-year risk of ICH. These risks 
can inform decisions about CCM treatment, by indirect 
comparison with estimates of the eﬀ ects of treatment. 
Future research is needed to externally validate our 
prognostic model and establish whether other factors 
(eg, genotype, pregnancy, and statin or antithrombotic 
drug use) are independently associated with ICH in 
addition to the two core predictors; even larger sample 
sizes will be needed for this research. Furthermore, 
long-term risks remain to be quantiﬁ ed for a disorder 
that is often diagnosed in young people, but has only 
been well recognised by MRI since the 1980s.4
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